Evidence map›Paper›PMID 36434151›Full record

ArticleImmunogenetics2023

Age-dependent effect of the IFIH1/MDA5 gene variants on the risk of critical COVID-19.

María G Muñiz-Banciella, Guillermo M Albaiceta, Laura Amado-Rodríguez, Estefanía Salgado Del Riego, Inés López Alonso, Cecilia López-Martínez, Paula Martín-Vicente, Marta García-Clemente, Tamara Hermida-Valverde, Ana I Enríquez-Rodriguez and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Immunogenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Frontiers in immunology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. TheInternational journal of molecular sciences · 2023
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

María G Muñiz-BanciellaGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
Guillermo M AlbaicetaUnidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central Asturias, Oviedo, Spain.
Laura Amado-RodríguezUnidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central Asturias, Oviedo, Spain.
Estefanía Salgado Del RiegoUnidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central Asturias, Oviedo, Spain.
Inés López AlonsoInstituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain.
Cecilia López-MartínezInstituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain.
Paula Martín-VicenteInstituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain.
Marta García-ClementeInstituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain.
Tamara Hermida-ValverdeNeumología, Hospital Universitario Central Asturias, Oviedo, Spain.
Ana I Enríquez-RodriguezNeumología, Hospital Universitario Central Asturias, Oviedo, Spain.
Cristina Hernández-GonzálezNeumología, Hospital Universitario Central Asturias, Oviedo, Spain.
Elías Cuesta-LlavonaGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
Victoria AlvarezGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
Juan GómezGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain.
Eliecer CotoGenética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain. eliecer.coto@sespa.es.ORCID 0000-0002-8649-9150
Hospital Universitario Central de Asturias · ESUniversidad de Oviedo · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MDA5, encoded by the IFIH1gene, is a cytoplasmic sensor of viral RNAs that triggers interferon (IFN) antiviral responses. Common and rare IFIH1 variants have been associated with the risk of type 1 diabetes and other immune-mediated disorders, and with the outcome of viral diseases. Variants associated with reduced IFN expression would increase the risk for severe viral disease. The MDA5/IFN pathway would play a critical role in the response to SARS-CoV-2 infection mediating the extent and severity of COVID-19. Here, we genotyped a cohort of 477 patients with critical ICU COVID-19 (109 death) for three IFIH1 functional variants: rs1990760 (p.Ala946Thr), rs35337543 (splicing variant, intron 8 + 1G > C), and rs35744605 (p.Glu627Stop). The main finding of our study was a significant increased frequency of rs1990760 C-carriers in early-onset patients (< 65 years) (p = 0.01; OR = 1.64, 95%CI = 1.18-2.43). This variant was also increased in critical vs. no-ICU patients and in critical vs. asymptomatic controls. The rs35744605 C variant was associated with increased blood IL6 levels at ICU admission. The rare rs35337543 splicing variant showed a trend toward protection from early-onset critical COVID-19. In conclusion, IFIH1 variants associated with reduced gene expression and lower IFN response might contribute to develop critical COVID-19 with an age-dependent effect.

Indexed as

COVID-19Diabetes Mellitus, Type 1DEAD-box RNA HelicasesHumansInterferon-Induced Helicase, IFIH1SARS-CoV-2DEAD-box RNA HelicasesIFIH1 protein, humanInterferon-Induced Helicase, IFIH1COVID-19Genetic associationIFIH1/MDA5SARS-CoV-2

Identifiers

PMID36434151
PMCPMC9702716
OpenAlexW4310224742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.